Thetis Pharmaceuticals, a developer of immuno-resolving therapies for treatment of inflammatory bowel disease, has received a Fast-Track Small Business Innovation Research Grant from the National Institutes of Health. The award provides up to $2.3 million to support development of Thetis’ TP-317 candidate as oral therapy for treatment of ulcerative colitis.   “TP-317 offers a fundamentally new approach to IBD treatment based on active resolution of inflammation and the promotion of tissu...